- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00002550
Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
A Phase III Comparison Between Concurrent Chemotherapy Plus Radiotherapy and Concurrent Chemotherapy Plus Radiotherapy Followed by Surgical Resection for Stage IIIA (N2) Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. It is not yet known if chemotherapy plus radiation therapy is more effective with or without surgery for lung cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of combining cisplatin, etoposide, and radiation therapy with or without surgery in treating patients who have stage IIIA non-small cell lung cancer.
연구 개요
상세 설명
OBJECTIVES:
Primary
- Compare the progression-free survival, median (2-year) survival, and long-term (5-year) survival in patients with newly diagnosed, stage IIIA (N2) non-small cell lung cancer treated with radiotherapy concurrently with cisplatin and etoposide with or without surgical resection.
Secondary
- Compare the patterns of local and distant failure in patients treated with these regimens.
- Determine the relationship of tobacco use, alcohol use, and diet with toxicity of these regimens and outcome in both men and women.
OUTLINE: This is a randomized, multicenter study. Patients are stratified by contralateral mediastinal sampling or biopsy (yes vs no), tumor stage (T1 vs T2 vs T3), and performance status (70-80% vs 90-100%). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive induction with cisplatin IV over 1 hour on days 1 and 8 and etoposide IV over 1 hour on days 1-5. Treatment continues every 4 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning within 24 hours of the first dose of chemotherapy, patients undergo induction radiotherapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity. Patients without local progression or distant metastases at 2-4 weeks after completion of course 2 undergo resection approximately 3-5 weeks after completion of course 2. All visible, accessible bronchopulmonary, hilar, and mediastinal lymph nodes are excised. The choice of surgical procedure (thoracotomy, lobectomy, or pneumonectomy with en bloc resection of tumor extending into the parietal pleura, chest wall, pericardium, or diaphragm) is at the discretion of the surgeon. Patients who undergo resection receive 2 additional courses of chemotherapy alone beginning 4-6 weeks postoperatively. Patients with unresectable disease or who are medically unfit for or refuse resection receive 2 additional courses of chemotherapy alone beginning immediately after completion of course 2.
- Arm II: Patients undergo induction chemoradiotherapy as in arm I but do not undergo resection. Patients without local progression or distant metastases within 1 week before anticipated completion of induction radiotherapy receive 2 additional courses of chemotherapy beginning immediately after completion of course 2. Patients without local or distant progression after completion of course 4 undergo boost radiotherapy for 8 days.
Patients are followed every 2 months for 1 year, every 3 months for 2 years, and then every 6 months thereafter.
PROJECTED ACCRUAL: A total of 510 patients will be accrued for this study within 4.9 years.
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Pretoria, 남아프리카, 0001
- Pretoria Academic Hospitals
-
-
-
-
Illinois
-
Urbana, Illinois, 미국, 61801
- CCOP - Carle Cancer Center
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202-5289
- Indiana University Cancer Center
-
Indianapolis, Indiana, 미국, 46202
- Veterans Affairs Medical Center - Indianapolis (Roudebush)
-
-
Iowa
-
Cedar Rapids, Iowa, 미국, 52403-1206
- CCOP - Cedar Rapids Oncology Project
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48106
- CCOP - Ann Arbor Regional
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68106
- CCOP - Missouri Valley Cancer Consortium
-
-
New York
-
Rochester, New York, 미국, 14642
- University of Rochester Cancer Center
-
-
Ohio
-
Cleveland, Ohio, 미국, 44106-5065
- Ireland Cancer Center
-
Toledo, Ohio, 미국, 43623-3456
- CCOP - Toledo Community Hospital Oncology Program
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19102-1192
- Hahnemann University Hospital
-
Pittsburgh, Pennsylvania, 미국, 15213-3489
- University of Pittsburgh Cancer Institute
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37232-6838
- Vanderbilt-Ingram Cancer Center
-
-
Wisconsin
-
Green Bay, Wisconsin, 미국, 54301
- CCOP - Green Bay
-
Milwaukee, Wisconsin, 미국, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, 미국, 53295
- Veterans Affairs Medical Center - Milwaukee (Zablocki)
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
Histologically or cytologically proven newly diagnosed, stage IIIA (T1-3, N2) non-small cell lung cancer
Eligible subtypes:
- Adenocarcinoma
- Large cell carcinoma
- Squamous cell carcinoma
- Nonlobar and nondiffuse bronchoalveolar cell carcinoma
Measurable or evaluable disease on chest x-ray and/or contrast CT scan
- Contrast thoracic CT required to complete staging
- Single primary bronchogenic tumor (no more than 1 parenchymal lung lesion)
Pleural effusions allowed if 1 of the following conditions is met:
- Negative cytology on thoracentesis if effusions present before mediastinoscopy or exploratory thoracotomy
- Effusion seen on CT scan but not on chest x-ray and deemed too small to tap under CT or ultrasound guidance
Positive ipsilateral mediastinal node(s) with or without positive ipsilateral hilar nodes
- Mediastinal nodes separate from primary lesion on CT scan or surgical exploration
- Histologic or cytologic proof of N2 disease by thoracotomy, mediastinoscopy, mediastinotomy, Chamberlain procedure, Wang needle, or fine needle aspiration under bronchoscopic or CT guidance
Nodal biopsy or aspiration waived if all of the following conditions are met:
- Paralyzed left true vocal cord documented by bronchoscopy or indirect laryngoscopy
- Nodes visible in Level 5 region on CT scan
- Distinct primary lesion separate from nodes on CT scan
- All mediastinal nodal involvement mapped (positive or negative)
No positive nodes in contralateral mediastinum (supraclavicular areas and higher) and neck
- Mediastinoscopy, mediastinotomy, Chamberlain procedure, or thoracotomy required for nodes larger than 1 cm on contrast CT scan
- Surgery waived if nodes negative or no larger than 1 cm on CT scan
- Lymphadenopathy allowed if biopsy proof of a benign cause
- No metastases by contrast CT or MRI scan of the brain, bone scan, CT scan of the lungs to exclude other ipsilateral or contralateral parenchymal lesions, and contrast CT scan of the upper abdomen including entire liver and adrenals
- No hepatomegaly or splenomegaly by physical examination or CT scan unless documentation of a benign cause
- No pericardial effusion
- No superior vena cava syndrome
- No prior diagnosis of lung cancer
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Karnofsky 90-100% (70-80% allowed if albumin at least 0.85 times lower limit of normal and weight loss no greater than 10% within 3 months before diagnosis)
Hematopoietic:
- White blood cell count (WBC) at least 4,000/mm^3 OR
- Granulocyte count at least 2,000/mm^3
- Platelet count normal
- Hemoglobin at least 10.0 g/dL (less than 8.5 g/dL allowed if no marrow involvement with tumor)
Hepatic:
- See Performance status
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)*
- Serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) no greater than 1.5 times ULN* NOTE: * Unless documentation of a benign cause
Renal:
- Creatinine clearance at least 50 mL/min
Cardiovascular:
- No myocardial infarction within the past 3 months
- No active angina
- No unstable arrhythmia
- No congestive heart failure
Pulmonary:
- Forced expiratory volume at one second (FEV1) at least 2.0 liters OR
- Predicted postresection FEV1 at least 800 mL based on quantitative V/Q scan
- Diffusion capacity of lung for carbon monoxide (DLCO) at least 50% predicted (corrected for hemoglobin) if pneumonectomy planned or likely after induction chemotherapy
Other:
- No clinically significant hearing loss unless willing to accept the potential of further loss
- No symptomatic peripheral neuropathy
- No peptic ulcer disease under active treatment
- No other medical illness not controllable by appropriate medical therapy
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or ductal or lobular carcinoma in situ of the breast
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No concurrent colony-stimulating factors
Chemotherapy:
- No prior chemotherapy for lung cancer
- No concurrent chemotherapy for another condition (such as arthritis)
Endocrine therapy:
- Not specified
Radiotherapy:
- No prior radiotherapy for lung cancer
Surgery:
- See Disease Characteristics
- No prior resection of primary tumor
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: RT + chemotherapy followed by surgery + chemotherapy
Induction radiation therapy (RT) + concurrent induction chemotherapy followed by surgery and additional chemotherapy
|
|
활성 비교기: RT + chemotherapy followed by chemotherapy + RT
Induction RT + concurrent induction chemotherapy followed by additional chemotherapy + RT
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Median overall survival
기간: From randomization to date of death or last follow-up. Analysis occurs after patients have been potentially followed for 2.5 years.
|
From randomization to date of death or last follow-up. Analysis occurs after patients have been potentially followed for 2.5 years.
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
Median Progression-free survival
기간: From randomization to date of death or last follow-up. Analysis occurs after patients have been potentially followed for 2.5 years.
|
From randomization to date of death or last follow-up. Analysis occurs after patients have been potentially followed for 2.5 years.
|
Patterns of local and distant failure
기간: From randomization to date of failure (local, regional or distant progression). Analysis occurs after patients have been potentially followed for 2.5 years.
|
From randomization to date of failure (local, regional or distant progression). Analysis occurs after patients have been potentially followed for 2.5 years.
|
공동 작업자 및 조사자
협력자
수사관
- 연구 의자: Robert C. Miller, MD, Mayo Clinic
- 연구 의자: David S. Ettinger, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- 연구 의자: David H. Johnson, MD, Vanderbilt-Ingram Cancer Center
- 수석 연구원: Kathy S. Albain, MD, Loyola University
- 연구 의자: Bruce E. Johnson, MD, Dana-Farber Cancer Institute
- 연구 의자: Mark R. Green, MD, Medical University of South Carolina
- 연구 의자: Yvon Cormier, MD, L'Hopital Laval
간행물 및 유용한 링크
일반 간행물
- Machtay M, Bae K, Movsas B, Paulus R, Gore EM, Komaki R, Albain K, Sause WT, Curran WJ. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):425-34. doi: 10.1016/j.ijrobp.2010.09.004. Epub 2010 Oct 25.
- Machtay M, Swann S, Komaki R, et al.: What is the meaning of local-regional control after chemoradiation for locally advanced NSCLC? An RTOG analysis. [Abstract] Lung Cancer 50 (Suppl 2): A-O-041, S17, 2005.
- Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009 Aug 1;374(9687):379-86. doi: 10.1016/S0140-6736(09)60737-6. Epub 2009 Jul 24.
- Albain KS, Swann RS, Rusch VR, et al.: Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). [Abstract] J Clin Oncol 23 (Suppl 16): A-7014, 624s, 2005.
- Albain KS, Scott CB, Rusch VR, et al.: Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09) . [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2497, 2003.
- Turrisi AT, Scott CB, Rusch VR, et al.: Randomized trial of chemoradiotherapy to 61 Gy [no S] versus chemoradiotherapy to 45 Gy followed by surgery [S] using cisplatin etoposide in stage IIIa non-small cell lung cancer (NSCLC): intergroup trial 0139, RTOG (9309). [Abstract] Int J Radiat Oncol Biol Phys 57 (2 Suppl): S125-6, 2003.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- RTOG-9309
- CDR0000063333
- CAN-NCIC-BR13
- CLB-9592
- E-R9309
- NCCTG-R9309
- NCI-94-C-0043
- SWOG-9336
- INT-0139
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
폐암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)모병피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Novartis Pharmaceuticals완전한신경내분비종양 | GI 오리진의 고급 NET | 고급 NET of Lung Origin미국, 콜롬비아, 이탈리아, 대만, 영국, 벨기에, 체코, 독일, 일본, 사우디 아라비아, 캐나다, 네덜란드, 스페인, 대한민국, 레바논, 오스트리아, 중국, 그리스, 남아프리카, 태국, 헝가리, 칠면조, 폴란드, 슬로바키아, 러시아 연방
-
Jonsson Comprehensive Cancer Center아직 모집하지 않음전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Rashmi Verma, MDNational Cancer Institute (NCI)모병거세저항성 전립선암 | 전이성 전립선 선암종 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.종료됨2기 전립선암 AJCC v8 | IIIA기 전립선암 AJCC v8 | IIIB기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | 3기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Assiut University아직 모집하지 않음South Egypt Cancer Institute(SECI)에서 소아 악성종양 환자에 대한 KDIGO 기준을 사용하여 AKI의 누적 발병률을 확인하기 위해
방사선 요법에 대한 임상 시험
-
Alpha Tau Medical LTD.European Organisation for Research and Treatment of Cancer - EORTC아직 모집하지 않음
-
Alpha Tau Medical LTD.모병
-
Alpha Tau Medical LTD.모병
-
Alpha Tau Medical LTD.모집하지 않고 적극적으로